Singapore - English - HSA (Health Sciences Authority)

bristol-myers squibb (singapore) pte. ltd. - abatacept - injection - 125mg

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - didanosine 125mg;   - capsule - 125 mg - active: didanosine 125mg   excipient: carmellose sodium diethyl phthalate gelatin methacrylic acid copolymer purified talc sodium starch glycolate tekprint tan sw-8010 titanium dioxide - videx ec in combination with other antiretroviral drugs, is indicated for the treatment of hiv infected adults.

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - didanosine 200mg;   - capsule - 200 mg - active: didanosine 200mg   excipient: carmellose sodium diethyl phthalate gelatin methacrylic acid copolymer purified talc sodium starch glycolate tekprint green sb-4020 titanium dioxide - videx ec in combination with other antiretroviral drugs, is indicated for the treatment of hiv infected adults.

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - didanosine 250mg;   - capsule - 250 mg - active: didanosine 250mg   excipient: carmellose sodium diethyl phthalate gelatin methacrylic acid copolymer purified talc sodium starch glycolate tekprint blue sb-6018 titanium dioxide - videx ec in combination with other antiretroviral drugs, is indicated for the treatment of hiv infected adults.

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - didanosine 400mg;   - capsule - 400 mg - active: didanosine 400mg   excipient: carmellose sodium diethyl phthalate gelatin methacrylic acid copolymer opacode red s-1-15094 opacode red s-1-15095 purified talc sodium starch glycolate titanium dioxide - videx ec in combination with other antiretroviral drugs, is indicated for the treatment of hiv infected adults.

Singapore - English - HSA (Health Sciences Authority)

bristol-myers squibb (singapore) pte. ltd. - entecavir - solution - 0.05mg/ml

Israel - English - Ministry of Health

bristol, myers squibb (israel) limited, israel - dasatinib - film coated tablets - dasatinib 100 mg - dasatinib - dasatinib - treatment of adult patients with : * newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. * chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib mesilate. * ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.

Israel - English - Ministry of Health

bristol, myers squibb (israel) limited, israel - nivolumab - concentrate for solution for infusion - nivolumab 10 mg/ml - nivolumab - unresectable or metastatic melanoma:opdivo as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and pediatric patients 12 years and older.adjuvant treatment of melanoma:opdivo is indicated for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected stage iib, iic, iii, or iv melanoma.metastatic non-small cell lung cancer:- opdivo, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer (nsclc), with no egfr or alk genomic tumor aberrations.- opdivo is indicated for the treatment of adult patients with metastatic non small cell lung cancer (nsclc) with progression on or after platinum-based chemotherapy.renal cell carcinoma:- opdivo as a single agent is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc) in patients who have received prior anti-angiogenic therapy.- opdivo in combination with ipilimumab is indicated for the first line treatment of adult patients with intermediate or poor risk, advanced renal cell carcinoma (rcc).- opdivo, in combination with cabozantinib, is indicated for the first-line treatment of adult patients with advanced rcc.classical hodgkin lymphoma:opdivo is indicated for the treatment of adult patients with classical hodgkin lymphoma (chl) that has relapsed or progressed after:* autologous hematopoietic stem cell transplantation (hsct) and brentuximab vedotin, or* 3 or more lines of systemic therapy that includes autologous hsct.squamous cell carcinoma of the head and neck:opdivo is indicated for the treatment of adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck (scchn) with disease progression on or after platinum-based therapy.microsatellite instability-high (msi-h) or mismatch repair deficient(dmmr) metastatic colorectal cancer:opdivo, as a single agent or in combination with ipilimumab, is indicated for the treatment of adult and pediatric patients 12 years and older with microsatellite instability-high (msi-h) or mismatch repair deficient (dmmr) metastatic colorectal cancer (crc) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.urothelial carcinoma:- opdivo is indicated for the adjuvant treatment of adult patients with urothelial carcinoma (uc) who are at high risk of recurrence after undergoing radical resection of uc.- opdivo (nivolumab) is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who: * have disease progression during or following platinum-containing chemotherapy * have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.hepatocellular carcinoma:opdivo, as a single agent or in combination with ipilimumab, is indicated for the treatment of adult patients with hepatocellular carcinoma (hcc) child-pugh a who have been previously treated with sorafenib.esophageal cancer:-opdivo is indicated for the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in adult patients who have received neoadjuvant chemoradiotherapy (crt). -opdivo is indicated for the treatment of adult patients with unresectable, advanced, recurrent or metastatic esophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based chemotherapy.- opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%.-opdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%.malignant pleural mesothelioma:opdivo, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma:opdivo, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the treatment of adult patients with unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.neoadjuvant treatment of resectable non-small cell lung cancer:opdivo, in combination with platinum-doublet chemotherapy, is indicated as neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer (nsclc).

Israel - English - Ministry of Health

bristol, myers squibb (israel) limited, israel - dasatinib - film coated tablets - dasatinib 20 mg - dasatinib - treatment of adult patients with : * newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. * chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib mesilate. * ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.

Israel - English - Ministry of Health

bristol, myers squibb (israel) limited, israel - dasatinib - film coated tablets - dasatinib 50 mg - dasatinib - treatment of adult patients with : * newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. * chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib mesilate. * ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.